MVA85A tuberculosis vaccine booster,
does it really help with Prevention of tuberculosis in BCG-vaccinated infants?
research showsGrade D. Tuberculosis occurred in 32/1399 (2.3%) versus 39/1395 (2.8%), an absolute difference of -0.5 points; vaccine efficacy was 17.3% (95% CI -31.9 to 48.2).
ads claimBCG effectiveness and effectiveness of a post-BCG booster candidate must be separated.
Useful facts when choosing a product
- MVA85A is a modified vaccinia Ankara vector expressing antigen 85A.
- All infants had received BCG.
- Post-BCG boosters remain a genuine development target.
Chamgap Semantic Classification Code
Candidate index · review held
M.mva85a-tuberculosis-vaccine-booster.UNK.tuberculosis-in-bcg-vaccinated-infants.prevent.placeboMedicinal interventions > MVA85A tuberculosis vaccine booster > Unknown > tuberculosis in BCG-vaccinated infants > Occurrence-prevention claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
BCG-vaccinated healthy infants were double-blind randomized and followed for up to 37 months. The Funding section listed Aeras, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium. MVA85A was developed at Oxford, with Emergent participating in the commercial development consortium.
Why this is classified as D (34)
One large null hard-outcome trial with a wide interval gives D with 34 points.
Counterpoint. The result does not negate BCG itself.
Rejudgment record. Cross-check applied — A 2,797-infant hard-outcome trial after BCG was null with a wide confidence interval
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Added TB prevention after BCG | D | No significant benefit. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Tameris et al. 2013 MVA85A 020 | Double-blind placebo-controlled phase 2b RCT | 2,797 infants | Aeras, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium (OETC) | Incident tuberculosis | 32/1399 vs 39/1395; efficacy 17.3% (95% CI -31.9 to 48.2), absolute difference -0.5 points | Large hard-outcome candidate-vaccine trial |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Evidence date: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of MVA85A Tuberculosis Vaccine for Preventing Tuberculosis in BCG-Vaccinated Infants — Evidence Grade D·34. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/mva85a-booster-bcg-vaccinated-infants-tuberculosis/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.